Ultraviolet A1 phototherapy for mycosis fungoides

K Olek-Hrab; W Silny; A Dańczak-Pazdrowska; A Osmola-Mańkowska; P A Sadowska; A Polańska; R Gniadecki; D Jenerowicz

doi:10.1111/ced.12001

Ultraviolet A1 phototherapy for mycosis fungoides

K Olek-Hrab, W Silny, A Dańczak-Pazdrowska, A Osmola-Mańkowska, P A Sadowska, A Polańska, R Gniadecki, D Jenerowicz

Dermatologisk og Venerologisk Afdeling og Videncenter for Sårheling BFH

31 Citationer (Scopus)

Abstract

Background. Mycosis fungoides (MF) is the most common form of primary cutaneous lymphoma, and is characterized by a malignant proliferation of CD4+ cells. Psoralen ultraviolet A (PUVA) irradiation is the most common treatment for cutaneous lesions. However, PUVA carries the risk of adverse reactions to psoralens and long-term risk of skin cancer. UVA1 may be a safer alternative. Aim. To assess the efficacy of UVA1 phototherapy in patients with early-stage MF (T1-T2). Methods. Four patients with early-stage MF were treated with 1630-2710 J/cm(2) UVA1 given in 29-40 fractions, and the effect was assessed by clinical examination and by high-resolution ultrasonography. Results. Complete clinical remission of MF was achieved in all cases. Conclusions. This preliminary report indicates that UVA1 phototherapy might be an efficient treatment for early-stage MF.

Originalsprog	Engelsk
Tidsskrift	Clinical and Experimental Dermatology
Vol/bind	38
Udgave nummer	2
Sider (fra-til)	126-30
Antal sider	5
ISSN	0307-6938
DOI	https://doi.org/10.1111/ced.12001
Status	Udgivet - 2013

Adgang til dokumentet

10.1111/ced.12001

Citationsformater

@article{3ab2b85b69424e6aa988147ef1c08cc8,

title = "Ultraviolet A1 phototherapy for mycosis fungoides",

abstract = "Background. Mycosis fungoides (MF) is the most common form of primary cutaneous lymphoma, and is characterized by a malignant proliferation of CD4+ cells. Psoralen ultraviolet A (PUVA) irradiation is the most common treatment for cutaneous lesions. However, PUVA carries the risk of adverse reactions to psoralens and long-term risk of skin cancer. UVA1 may be a safer alternative. Aim. To assess the efficacy of UVA1 phototherapy in patients with early-stage MF (T1-T2). Methods. Four patients with early-stage MF were treated with 1630-2710 J/cm(2) UVA1 given in 29-40 fractions, and the effect was assessed by clinical examination and by high-resolution ultrasonography. Results. Complete clinical remission of MF was achieved in all cases. Conclusions. This preliminary report indicates that UVA1 phototherapy might be an efficient treatment for early-stage MF.",

author = "K Olek-Hrab and W Silny and A Da{\'n}czak-Pazdrowska and A Osmola-Ma{\'n}kowska and Sadowska, {P A} and A Pola{\'n}ska and R Gniadecki and D Jenerowicz",

note = "{\textcopyright} The Author(s). CED {\textcopyright} 2012 British Association of Dermatologists.",

year = "2013",

doi = "10.1111/ced.12001",

language = "English",

volume = "38",

pages = "126--30",

journal = "Clinical and Experimental Dermatology",

issn = "0307-6938",

publisher = "Oxford University Press",

number = "2",

}

TY - JOUR

T1 - Ultraviolet A1 phototherapy for mycosis fungoides

AU - Olek-Hrab, K

AU - Silny, W

AU - Dańczak-Pazdrowska, A

AU - Osmola-Mańkowska, A

AU - Sadowska, P A

AU - Polańska, A

AU - Gniadecki, R

AU - Jenerowicz, D

PY - 2013

Y1 - 2013

N2 - Background. Mycosis fungoides (MF) is the most common form of primary cutaneous lymphoma, and is characterized by a malignant proliferation of CD4+ cells. Psoralen ultraviolet A (PUVA) irradiation is the most common treatment for cutaneous lesions. However, PUVA carries the risk of adverse reactions to psoralens and long-term risk of skin cancer. UVA1 may be a safer alternative. Aim. To assess the efficacy of UVA1 phototherapy in patients with early-stage MF (T1-T2). Methods. Four patients with early-stage MF were treated with 1630-2710 J/cm(2) UVA1 given in 29-40 fractions, and the effect was assessed by clinical examination and by high-resolution ultrasonography. Results. Complete clinical remission of MF was achieved in all cases. Conclusions. This preliminary report indicates that UVA1 phototherapy might be an efficient treatment for early-stage MF.

AB - Background. Mycosis fungoides (MF) is the most common form of primary cutaneous lymphoma, and is characterized by a malignant proliferation of CD4+ cells. Psoralen ultraviolet A (PUVA) irradiation is the most common treatment for cutaneous lesions. However, PUVA carries the risk of adverse reactions to psoralens and long-term risk of skin cancer. UVA1 may be a safer alternative. Aim. To assess the efficacy of UVA1 phototherapy in patients with early-stage MF (T1-T2). Methods. Four patients with early-stage MF were treated with 1630-2710 J/cm(2) UVA1 given in 29-40 fractions, and the effect was assessed by clinical examination and by high-resolution ultrasonography. Results. Complete clinical remission of MF was achieved in all cases. Conclusions. This preliminary report indicates that UVA1 phototherapy might be an efficient treatment for early-stage MF.

U2 - 10.1111/ced.12001

DO - 10.1111/ced.12001

M3 - Journal article

C2 - 23082901

SN - 0307-6938

VL - 38

SP - 126

EP - 130

JO - Clinical and Experimental Dermatology

JF - Clinical and Experimental Dermatology

IS - 2

ER -

Ultraviolet A1 phototherapy for mycosis fungoides

Abstract

Adgang til dokumentet

Fingeraftryk

Citationsformater